Get the Stockscreener App
91.57
1.29%
1.17
After Hours:
92.00
0.43
+0.47%
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $91.57, with a volume of 1.23M.
It is up +1.29% in the last 24 hours and up +8.93% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$90.40
Open:
$91.28
24h Volume:
1.23M
Relative Volume:
1.24
Market Cap:
$45.29B
Revenue:
$9.76B
Net Income/Loss:
$1.16B
P/E Ratio:
39.13
EPS:
2.34
Net Cash Flow:
$665.00M
1W Performance:
+0.34%
1M Performance:
+8.93%
6M Performance:
-0.88%
1Y Performance:
+22.13%
1-Day Range:
$91.02
$91.75
1-Week Range:
$90.09
$92.84
52-Week Range:
$74.53
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
91.57 | 45.29B | 9.76B | 1.16B | 665.00M | 2.34 |
|
ISRG
Intuitive Surgical Inc
|
579.65 | 206.74B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
242.42 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
RMD
Resmed Inc
|
240.46 | 35.33B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
331.04 | 24.01B | 2.88B | 499.60M | 321.60M | 6.74 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Alcon: An Eyecare Leader With Strong Profit Margins, But Overheated Valuation - Seeking Alpha
Alcon Laboratories is considering a major $100M expansion of its Fort Worth campus - AOL
Alcon Loses Bid to Veto Aurion IPO, Can Still Oppose Listing (1) - Bloomberg Law
Intraocular Lens Market Forecast and Company Analysis - GlobeNewswire
Intraocular Lens Market Forecast and Company Analysis Report 2025-2033 Featuring Alcon, Bausch Health, Hoya, Johnson & Johnson, STAAR Surgical Co, Carl Zeiss Meditec, and Novartis - Yahoo Finance
Alcon stock price target cut to $106 by Needham, maintains Buy - MSN
Alcon Breaks Above 200-Day Moving AverageBullish for ALC - Nasdaq
Artificial Tears Market Overall Study Report 2025-2032 | - openPR
Alcon stock price target cut to $105 by KeyBanc - MSN
Apple To $253? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Do Options Traders Know Something About Alcon (ALC) Stock We Don't? - Yahoo Finance
First Week of March 21st Options Trading For Alcon (ALC) - Nasdaq
Alcon Inc (ALC) Shares Up 3.7% on Jan 21 - GuruFocus.com
Modernizing a Legacy Application on AWS Serverless with Alcon - AWS Blog
Modernizing a Legacy Application on AWS Serverless with Alcon | Case Study | AWS - AWS Blog
Alcon to Seek M&A -January 14, 2025 at 07:30 pm EST - Marketscreener.com
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - Yahoo Finance
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Redburn raises Alcon stock rating to Buy By Investing.com - Investing.com Australia
Redburn raises Alcon stock rating to Buy - Investing.com
Dry Eye Disease Market Is Booming Worldwide 2025-2032 | Novartis - openPR
Alcon Inc. (VTX:ALC) is favoured by institutional owners who hold 63% of the company - Simply Wall St
Seeing Brilliance in APAC: Alcon’s Vision Care Innovations and Eye Health Mission - BSA bureau
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Alcon Laboratories issues recall for Systane eye drops due to fungal contamination - Top Class Actions
News Release – DOH Issues Recall Alert For Alcon Laboratories Systane Brand Lubricant Eye Drops Due to Fungal - EIN News
DOH issues recall alert for Alcon Laboratories Systane Brand Lubricant Eye Drops - Maui Now
Alcon Labs recalling eye drops - Valley News
Alcon Laboratories Recalls Systane Eye Drops Nationwide Over Fungal Contamination Risk - Black Enterprise
Alcon's (VTX:ALC) investors will be pleased with their respectable 41% return over the last five years - Simply Wall St
Alcon recalls Systane eye drops due to potential fungal contamination risk - WRAL News
Alcon Laboratories Recalls Systane Eye Drops Over Fungal Risk - Franklin County Free Press
Alcon Labs Recalls Systane Lubricant Eye Drops Over Fungal Contamination - Nasdaq
Refractive Surgery Market Growth in Future Scope 2024-2031 | - openPR
Retinal Laser Photocoagulation Market Top PlayersAlcon, A.R.C Laser, Ellex Medical, Carl Zeiss, Quantel Medical. - openPR
Here's Why Alcon (ALC) is a Strong Growth Stock - MSN
Aesthetic Ophthalmology Devices Business Analysis Report 2024-2030 Featuring 40+ Key Players Including Abbott, Bausch & Lomb, Alcon, Allergan, Carl Zeiss, Haag Streit, Meditec, Topcon, Zeimer - GlobeNewswire
Alcon Laboratories Issues Voluntary Nationwide Recall of One (1) Lot of Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count (Lot 10101), Due to Fungal Contamination - US Recall News
Alcon a top pick for 2025 at Needham on upcoming product launches - MSN
Alcon Top Pick for 2025 at Needham, added to Conviction List - MSN
Alcon stock named top pick for 2025 by Needham, positive on margin and earnings growth - Investing.com Australia
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):